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Tissue infiltration of activated lymphocytes is a
hallmark of transplant rejection and organ-specific
autoimmune diseases. Migration and activation of
lymphocytes depend on DOCK2, an atypical Rac
activator predominantly expressed in hematopoietic
cells. Although DOCK2 does not contain Dbl
homology domain typically found in guanine nucleo-
tide exchange factors, DOCK2 mediates the GTP-
GDP exchange reaction for Rac through its DHR-2
domain. Here, we have identified 4-[30-(200-chloro-
phenyl)-20-propen-10-ylidene]-1-phenyl-3,5-pyrazoli-
dinedione (CPYPP) as a small-molecule inhibitor of
DOCK2. CPYPP bound to DOCK2 DHR-2 domain
in a reversible manner and inhibited its catalytic
activity in vitro. When lymphocytes were treated
with CPYPP, both chemokine receptor- and antigen
receptor-mediated Rac activation were blocked, re-
sulting in marked reduction of chemotactic response
and T cell activation. These results provide a rational
of and a chemical scaffold for development of the
DOCK2-targeting immunosuppressant.
INTRODUCTION
Tissue infiltration of activated lymphocytes is a hallmark of
transplant rejection and organ-specific autoimmune diseases
(Gerard and Rollins, 2001; Luster et al., 2005). This process
involves a complex cascade of molecular interactions and488 Chemistry & Biology 19, 488–497, April 20, 2012 ª2012 Elseviercellular responses, including the chemokine-dependent migra-
tion of lymphocytes, the recognition by T cell receptors (TCRs)
of allo- or self-peptides bound to major histocompatibility
complex (MHC) molecules, the engagement of costimulation
and adhesion molecules with their ligands, and the activation
of multiple intracellular signal transduction pathways that lead
to the release of cytokines that are key to lymphocyte expansion
and tissue destruction. Thus far, TCR signaling pathways have
been the major targets for drug discovery, and the resultant
calcineurin inhibitors, cyclosporine and FK506, successfully
controlled allograft rejection in clinical and experimental trans-
plantation (Denton et al., 1999). More recently, FTY720, which
acts as a functional antagonist for sphingosine 1-phosphate
receptor and inhibits lymphocyte egress from the secondary
lymphoid organs, has been developed as a novel immunomod-
ulatory drug (Brinkmann et al., 2010; Mandala et al., 2002).
However, because both migration and activation of lymphocytes
requires remodeling of the actin cytoskeleton (Dustin and
Cooper, 2000; Vicente-Manzanares and Sa´nchez-Madrid,
2004), inhibition of the cytoskeletal reorganization in lympho-
cytes may be an alternative approach to control transplant
rejection and organ-specific autoimmune diseases.
Rac is the small GTPase that regulates membrane polarization
and cytoskeletal dynamics in varied biological settings (Hall,
1998). Like other small GTPases, Rac cycles between GDP-
bound inactive and GTP-bound active states, and stimulus-
induced formation of the active Rac is mediated by guanine
nucleotide exchange factors (GEFs). The critical role of Rac
activation in lymphocyte migration has been well established
(Faroudi et al., 2010; Tybulewicz and Henderson, 2009). More-
over, the activation of Rac has been implicated in immunological
synapse formation, a large-scale molecular movement at the
interface between T cells and antigen presenting cells (APCs),Ltd All rights reserved
Figure 1. Synthesis of CPYPP (1) and Its Geometrically Pure Isomers
Reagents and conditions: a, Et3N, THF, –10
C, 68%, 3:1 inseparable mixture;
b, 1 M NaOH in EtOH, room temperature, 58%; c, 3-(20-Chlorophenyl)prope-
nal, proline (10 mol %), THF, room temperature, 70%; d, Wash with CHCl3,
90%; e, SiO2 medium-pressure columnwith AcOEt/hexanes = 2/5 elution. The
synthesis and purification of CPYPP and its geometrically pure isomers (12, 13)
are described in Supplemental Experimental Procedures in detail.
See also Figure S1.
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An Inhibitor that Blocks Rac Activation by DOCK2which is considered to be critical for sustained T cell activation
(Dustin and Cooper, 2000; Villalba et al., 2001; Yu et al., 2001).
Therefore, Rac activation would be a target to manipulate
lymphocyte functions. However, Rac is composed of three iso-
forms, and the ubiquitous expression and redundancy of Rac
isoforms preclude using Rac itself as a drug target.
DOCK2 is a member of the CDM family of proteins (Caeno-
rhabditis elegans CED-5, mammals DOCK180, and Drosophila
melanogaster Myoblast City) and is predominantly expressed
in hematopoietic cells (Reif and Cyster, 2002). Although
DOCK2 does not contain the Dbl homology (DH) domain and
the Pleckstrin homology (PH) domain typically found in GEFs,
DOCK2 catalyzes the GTP–GDP exchange reaction for Rac by
means of its DHR-2 (DOCK homology region 2; also known as
Docker and CZH2) domain (Brugnera et al., 2002; Coˆte´ and
Vuori, 2002; Meller et al., 2002). DOCK2 is essential for chemo-
kine receptor- and antigen receptor-mediated Rac activation,
and plays a critical role in migration and activation of lympho-
cytes (Fukui et al., 2001; Nombela-Arrieta et al., 2004; Nom-
bela-Arrieta et al., 2007; Sanui et al., 2003; Shulman et al.,
2006). Consistent with the critical roles of DOCK2 in lymphocyte
functions, DOCK2 deficiency enables long-term survival of
cardiac allografts (Jiang et al., 2005) and abrogates development
of autoimmune diabetes in NODmice (our unpublished observa-
tion), a model for human type I diabetes (Anderson and Blue-
stone, 2005). Thus, DOCK2 may serve as a molecular target
for controlling immune-related disorders.
Here, we report identification and characterization of a
small-molecule, 4-[30-(200-chlorophenyl)-20-propen-10-ylidene]-1-
phenyl-3,5-pyrazolidinedione (CPYPP). We found that CPYPP
binds to the DOCK2 DHR-2 domain (DOCK2DHR-2) in a reversible
manner and inhibits its catalytic activity. Although overexpres-
sion of DOCK2, Tiam1, or Trio induced Rac activation in human
embryonic kidney 293T (HEK293T) cells, CPYPP suppressed
DOCK2-mediated Rac activation, without affecting Rac activa-
tion by the classical GEFs. More importantly, treatment ofChemistry & Biology 19,lymphocytes with CPYPP blocked DOCK2-mediated Rac acti-
vation and inflammatory responses in vitro and in vivo. Our
results thus provide a rational of and a chemical scaffold for
development of the DOCK2-targeting immunosuppressant.
RESULTS
Identification of CPYPP as a Small-Molecule Inhibitor
of DOCK2
DOCK2 binds to Rac through its DHR-2 domain and mediates
GTP–GDP exchange reaction (Brugnera et al., 2002; Coˆte´
and Vuori, 2002). Therefore, this interaction would be the first
target to block DOCK2-mediated inflammatory responses. We
screened 9,392 chemical compounds in terms of their ability to
inhibit interaction between DOCK2DHR-2 and Rac1 (see Table
S1 available online), and identified 131 candidates including
CPYPP (compound 1; Figures 1 and 2A). CPYPP inhibited the
GEF activity of DOCK2DHR-2 for Rac1 in a dose-dependent
manner, with a half-maximal inhibitory concentration (IC50) of
22.8 ± 2.4 mM (Figure 2B). This inhibitory activity was indepen-
dent on length of preincubation time, ranging from 2 min to
30 min (Figure S2). In addition, CPYPP was nontoxic when
applied to spleen cells or thymoma cells (BW5147a–b–) at
100 mM for 3 hr or 3 days, respectively (Figure S2). Then, CPYPP
was selected and synthesized in gram-scales for further evalua-
tion (Figures 1 and S1).
Recent structure of DOCK2DHR-2 complexed with Rac (Kul-
karni et al., 2011) indicates that the DHR-2 domain of DOCK2
is also organized into three lobes (lobes A, B, and C), as in
DOCK9 DHR-2 (Yang et al., 2009). Deletion of the amino acid
sequence corresponding to the lobe A (residues 1,195–1,335)
in DOCK2DHR-2 did not affect its GEF activity in vitro (Figure 2B),
indicating that Rac binding site and catalytic center are gener-
ated entirely from lobes B and C. As expected, Rac1 activation
by this mutant (DOCK2DHR-2DlobeA) was also inhibited by CPYPP
in vitro, although the IC50 value was a little bit higher than that
for wild-type DOCK2DHR-2 (Figure 2B). To determine whether
CPYPP binds to DHR-2 or Rac1, we utilized saturation transfer
difference (STD)-nuclear magnetic resonance (NMR) spectros-
copy (Meyer and Peters, 2003), which allows detection of weak
ligand binding by revealing the spatial proximity between ligand
protons and protein protons. Protein concentration used was
1 mM, and the ligands were added in 100-fold molar excess.
Therefore, only the ligand 1H signals were observed in the STD
spectra, and the protein 1H signals were invisible with the
assistance of the suppressive effect of the T1r filter in the
NMR pulse sequence. By irradiation of the methyl region of
the spectrum, all of the 1H signals of CPYPP showed the same
degree of reduction in intensity (average, –23%) in the presence
of the DOCK2DHR-2DlobeA (Figure 2C). In contrast, no significant
difference was observed when CPYPP was mixed with Rac1
(Figure 2C). Thus, CPYPP inhibits Rac GEF activity of DOCK2
by binding to the DHR-2 domain.
DOCK proteins are classified into four subfamilies (DOCK-A,
-B, -C, and -D) based on their structures and substrate speci-
ficity (Coˆte´ and Vuori, 2002). For example, DOCK180 and
DOCK5, as well as DOCK2, belong to DOCK-A subfamily and
act as Rac GEFs. On the other hand, DOCK9, a member of
DOCK-D subfamily, catalyzes Cdc42 activation through its488–497, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 489
Figure 2. CPYPP Inhibits Rac GEF Activity
of DOCK2 through Interaction with DHR-2
Domain
(A) Structure of CPYPP. Ha-Hl correspond to the
1H spectra in (C).
(B) Concentration-dependent inhibition by CPYPP
of in vitro GEF activity of DOCK2DHR-2 with or
without lobe A. Dose response curves and IC50
values (mean ± SD of three independent experi-
ments) are shown in lower panels.
(C) The STD-NMR analysis showing that CPYPP
binds to DOCK2DHR-2, but not to Rac. The
expanded region of the 1D 1H NMR spectra of
CPYPP with (+SAT) or without (–SAT) saturation of
the protein signals of DOCK2DHR-2DlobeA or Rac1.
The impurity peak is denoted by x.
(D) Comparison of inhibitory activity of CPYPP
among DOCK family proteins. The DHR-2 domain
lacking lobe A was prepared from each molecule
and analyzed for its GEF activity toward Rac
(DOCK2, DOCK180, and DOCK5) or Cdc42
(DOCK9) in the presence of various concentra-
tions of CPYPP. Graph shows IC50 values (mean ±
SD of three independent experiments) for each
protein. **p < 0.01.
See also Figure S2 and Table S1.
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An Inhibitor that Blocks Rac Activation by DOCK2DHR-2 domain (Meller et al., 2002). To address the specificity of
CPYPP, we compared the effect of CPYPP on the GEF activity of
these DOCK proteins in vitro. CPYPP inhibited the Rac GEF
activity of DOCK180DHR-2DlobeA and DOCK5DHR-2DlobeA with the
IC50 value comparable to that for DOCK2
DHR-2DlobeA (Figure 2D).
However, CPYPP was much less effective in inhibition of
DOCK9DHR-2DlobeA-mediated Cdc42 activation (Figure 2D).
These results indicate that, although the inhibitory effect of
CPYPP is not specific to DOCK2, CPYPP is able to discriminate
the structural difference among DOCK subfamily members.
Structural Features of CPYPP
To determine the structure of CPYPP required for its inhibitory
effect, we synthesized CPYPP analogs (Figures 3A and S1)
and compared their effects on the Rac GEF activity of
DOCK2DHR-2 in vitro. When the double bonds were saturated
through hydrogenation in compound 2, the inhibitory activity
was markedly decreased (Figure 3B). In contrast, both
compound 3 with one double bond and compound 4 with three
double bonds inhibited DOCK2-mediated Rac activation with
IC50 values comparable to that of CPYPP with two double bonds
(Figure 3C). Thus, at least one double bond is essential for the
inhibitory activity of CPYPP. Another important feature of CPYPP
would be a chloride substituent at the ortho (200)-position of an
aryl group on the conjugated double bonds. We found that the
inhibitory activity was significantly suppressed in nonsubstituted
compound 5 and compounds 6–9 with hydroxy, fluoride,
bromide, and methyl groups, respectively, at the ortho-position
(Figure 3C). However, the position of the chloride group on the
aromatic ring did not critically affect the inhibitory activity
(Figures 3A and 3C; see compounds 10 and 11).490 Chemistry & Biology 19, 488–497, April 20, 2012 ª2012 ElsevierThe importance of the electron-deficient double bonds in
CPYPP may raise the possibility that its inhibitory effect is
mediated by covalent adducts via Michael addition. To address
this possibility, we analyzed the binding of CPYPP to
DOCK2DHR-2DlobeA using a surface plasmon resonance (SPR)-
based instrument. Although compound 7 with fluoride at the
ortho-position did not show any binding to DOCK2DHR-2DlobeA,
CPYPP bound to DOCK2DHR-2DlobeA in a reversible manner (Fig-
ure 3D). In addition, we found that DOCK2DHR-2 treated with
CPYPP normally retained the GEF activity after removable of
CPYPP by gel filtration (Figure S3). These results indicate that
inhibition by CPYPP is reversible.
CPYPP and all the analogs exist as hardly separable equilib-
rium mixtures (1:1 to 1.6:1) of two geometrical isomers at the
C4=C10 double bond (Figure 4A). Cis isomer 12 is less soluble
to various organic solvents than trans isomer 13, allowing for
isolation of cis isomer 12 as a pure solid form by washing
a mixture with chloroform for several times. On the other
hand, trans isomer 13 was isolated by medium-pressure silica
gel column chromatography. The configuration of 12 and 13
was determined from the comparison of the two coupling
constants, 3JC3-H10 and
3JC5-H10 across the C4=C1
0 double
bond (Figure S4). Isolated 12 and 13 readily equilibrated each
other when dissolved in solution (such as DMSO, methanol,
and acetone) at ambient temperature, giving a 1:1 mixture of
two isomers. Even so, isolated 12 and 13 were quickly sub-
jected to the Rac GEF activity assay to obtain preliminary infor-
mation about the double bond geometry-activity relationship.
As a result, cis isomer 12 exhibited slightly higher activity
than CPYPP (1:1 mixture of 12 and 13), whereas trans isomer
13 did not show any inhibitory activity (Figure 4B). These resultsLtd All rights reserved
Figure 3. Structure-Activity Relationship of CPYPP
(A) CPYPP analogs used in this study (2–11).
(B) Importance of the conjugated double bonds and the chloride substituent for the inhibitory activity of CPYPP. Rac GEF activity of DOCK2DHR-2 was analyzed
in vitro in the presence of compounds 2, 3, or 7.
(C) Comparison of IC50 values for DOCK2
DHR-2-mediated Rac GEF activity among CPYPP analogs.
(D) SPR-based analysis showing that CPYPP, but not compound 7, binds to DOCK2DHR-2DlobeA in a reversible manner. The graph indicates the response levels
normalized by dividing the measured response units by the molecular weight. Data are mean ± SD of three independent experiments. **p < 0.01.
See also Figure S3.
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An Inhibitor that Blocks Rac Activation by DOCK2suggest that the inhibitory activity of CPYPP resides in cis
isomer.
CPYPP Is a Cell-Active Inhibitor of DOCK2
To examine whether CPYPP is a cell-active inhibitor, we ex-
pressed DOCK2 in HEK293T cells, and analyzed Rac activation
in the presence or absence of CPYPP. Although overexpression
of DOCK2 induced Rac activation in HEK293T cells, this activa-
tion was markedly suppressed by treating the cells with CPYPP
(1) at 100 mM for 1 hr before assay (Figure 5A). Similar inhibition
was obtained when HEK293T cells were treated with CPYPP
analogs such as 3, 10, or 11 (Figure 5A), all of which exhibited
IC50 values <30 mM in vitro (Figure 3C). Indeed, except forChemistry & Biology 19,compounds 4 and 6, the IC50 values were well correlated to
the degrees of inhibition of DOCK2-mediated Rac activation in
HEK293T cells (Figure 5A). On the other hand, treatment with
CPYPP did not significantly inhibit Rac activation by Tiam1 and
Trio under the same experimental condition (Figure 5B). These
results indicate that CPYPP is able to distinguish DOCK2 from
the Dbl-like GEFs and inhibit DOCK2-mediated Rac activation
in cells.
Inhibition by CPYPP of Lymphocyte Migration
To examine whether CPYPP inhibits DOCK2-dependent
lymphocyte functions, we first analyzed the effect of CPYPP
on chemokine-induced Rac activation. As previously reported488–497, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 491
Figure 4. Inhibitory Activity of CPYPP Resides in cis Isomer
(A) Structure of cis (12) and trans (13) isomers of CPYPP.
(B) The effect of cis and trans isomers on in vitro Rac GEF activity. Upon
isolation, cis and trans isomers of CPYPP were quickly subjected to in vitro
GEF assays.
See also Figure S4.
Figure 5. CPYPP Is a Cell-Active Inhibitor of DOCK2
(A) Comparison of inhibitory activity of CPYPP and its analogs for DOCK2-
mediated Rac activation in HEK293T cells. The correlation coefficient between
IC50 values and the percentage inhibition (mean of three independent exper-
iments) was 0.80. Compounds 4 and 6, and inactive compounds (2, 7, and 9)
that are excluded from the calculation are expressed as open circles.
(B) Selective inhibition by CPYPP of DOCK2-mediated Rac activation in
HEK293T cells. Results are expressed as the ratio of GTP-bound Rac to
total Rac after normalization of the value of DMSO-treated cells to an arbitrary
unit 1 for each GEF. Data are mean ± SD of four independent experiments.
*p < 0.05.
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An Inhibitor that Blocks Rac Activation by DOCK2(Fukui et al., 2001), chemokine-induced Rac activation was
severely impaired in DOCK2 deficient (DOCK2–/–) T and B cells,
indicating that this process is largely dependent on DOCK2
(Figures 6A and 6B). Although vehicle (DMSO) alone did not
show any inhibitory effect, pretreatment of T cells or B cells
with CPYPP at 100 mM for 1 hr markedly suppressed Rac activa-
tion in response to CCL21 or CXCL13, respectively (Figures 6A
and 6B). Consistent with this finding, treatment with CPYPP
effectively inhibited migratory response of T cells and B cells to
these chemokines in a dose-dependent manner (Figures 6C
and 6D). Lymphocytes also express DOCK5 (our unpublished
observation). When CPYPP was applied to DOCK2–/– lympho-
cytes, their migration defects were further augmented (Figures
6C and 6D), probably because of the cross-reactivity of CPYPP
to DOCK5.
To examine whether the effect of CPYPP could be extended
to in vivo situation, we first tested administration route and
dosage of CPYPP by measuring its plasma concentration using
liquid chromatography-tandem mass spectrometry (LC-MS/
MS). When 2.5 mg/kg of CPYPP was administrated intrave-
nously, the plasma concentration of CPYPP was only 2.4 mM
at 30 min (Figure S5). However, by intraperitoneally injecting
250 mg/kg of CPYPP into mice, the plasma concentration of
CPYPP reached to 11.3 mM at 30 min and 10.9 mM at 1 hr,
respectively (Figure S5). With this dose and administration
route, we examined the effect of CPYPP on lymphocyte
homing in vivo. For this purpose, we adoptively transferred
spleen cells from mice that had been made by a ‘‘knock-in’’
strategy to express endogenous DOCK2 as a fusion protein
with green fluorescent protein (GFP) (Nishikimi et al., 2009).
Without pretreatment with CPYPP, 0.19% of the injected
T cells, on an average, migrated to the peripheral lymph nodes
of the recipient mice (Figure 6E). However, intraperitoneal injec-
tion of CPYPP (5 mg per mouse) 1 hr before adoptive transfer492 Chemistry & Biology 19, 488–497, April 20, 2012 ª2012 Elsevierreduced the percentage of the migrated T cells to <25% of the
control level (Figure 6E). Similar, but less remarkable effect,
was observed when T cell homing to the spleen was analyzed
(Figure 6E). On the other hand, intravenous injection of 0.05 mg
of CPYPP did not show any inhibitory effect on lymphocyte
homing in vivo (Figure 6E).
Inhibition by CPYPP of Leukocyte Activation
Having found that CPYPP inhibitsmigratory response of lympho-
cytes, we next examined the effect of CPYPP on T cell activation.
DOCK2 is a major Rac GEF acting downstream of TCRs (Sanui
et al., 2003). Consistent with this, TCR-mediated Rac activation
was almost completely lost in T cells treated with CPYPP at
100 mM for 1 hr (Figure 7A). CD4+ T cells from C57BL/6 mice
vigorously proliferated when cultured for 3 days with APCs
from B10.BR mice (Figure 7B). However, this mixed lymphocyte
reaction (MLR) was blocked by cultivating CD4+ T cells and
APCs in the presence of CPYPP at the concentration of
12.5 mM (Figure 7B). This assay was performed in completeLtd All rights reserved
Figure 6. CPYPP Blocks Lymphocyte
Migration In Vitro and In Vivo
(A and B) The effect of CPYPP on Rac activation in
WT and DOCK2–/– T cells (A) or B cells (B) stimu-
lated with CCL21 or CXCL13, respectively.
Results are expressed as the ratio of GTP-bound
Rac to total Rac after normalization of the 15 s (A)
or 20 s (B) value of DMSO-treated cells to an
arbitrary unit 1. Data are mean ± SD of three
independent experiments.
(C and D) Inhibition by CPYPP of migratory
response ofWT and DOCK2–/– T cells (C) or B cells
(D) to CCL21 or CXCL13, respectively. NC, no
chemokine stimulation. Data are mean ± SD of
triplicate samples and are representative of three
independent experiments.
(E) Suppression of lymphocyte homing to
secondary lymphoid organs in mice treated with
CPYPP. Numbers in dot plots indicate the
percentage of GFP+ cells in CD3+ T cells. In
graphs, results are expressed as the percentage
ofmigrated T cells to total injected T cells. Data are
mean ± SEM of mice treated with CPYPP intra-
peritoneally (i.p.; 5 mg per mouse; n = 9) or intra-
venously (i.v.; 0.05 mg per mouse; n = 4), and are
representative of two independent experiments.
(A–E) *p < 0.05; **p < 0.01.
See also Figure S5.
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An Inhibitor that Blocks Rac Activation by DOCK2RPMI1640 medium supplemented with 10% fetal calf serum
(FCS), whereas the effect of CPYPP on lymphocyte migration
was examined in RPMI1640 medium containing 0.5% bovine
serum albumin (BSA). Because CPYPP was more effective in
MLR than in migration assay (see Figure 6C), the efficiency of
CPYPP uptake by lymphocytesmight be different between these
culture conditions. Indeed, we found that the intracellular
content of CPYPP was much higher when splenocytes were
incubated with CPYPP in complete RPMI1640 medium supple-
mented with 10% FCS (Figure S6).
By recognizing nucleic acid ligands through TLR7 and TLR9,
pDCs produce not only inflammatory cytokines, but also large
amounts of type I IFNs (Gilliet et al., 2008). This type I IFN induc-Chemistry & Biology 19, 488–497, April 20, 2012tion has been implicated in the pathogen-
esis of certain autoimmune diseases
such as psoriasis and systemic lupus
erythematosus (Blanco et al., 2001;
Nestle et al., 2005). Because DOCK2–
Rac axis is critical in pDCs for TLR-medi-
ated induction of type I IFNs, but not
inflammatory cytokines (Gotoh et al.,
2010), we also examined the effect of
CPYPP on pDC activation. When pDCs
were stimulated with A-type CpG DNA,
a TLR9 ligand, activated Rac was readily
detected (Figure 7C). However, treatment
with CPYPP severely impaired CpG-A-
induced Rac activation in pDCs (Fig-
ure7C), resulting in lossof IFN-a induction
without affecting IL-12p40 levels (Fig-
ure 7D). Collectively, these results indi-cate that treatment with CPYPP faithfully reproduces DOCK2-
deficient phenotypes in lymphocytes and pDCs.
DISCUSSION
Rac is an important signaling molecule that controls diverse
cellular functions, including migration and activation of lympho-
cytes (Faroudi et al., 2010; Hall, 1998; Tybulewicz and Hender-
son, 2009; Villalba et al., 2001; Yu et al., 2001). Thus far, several
chemical inhibitors acting at different steps of Rac signaling
have been identified. For example, NSC23766 or EHT 1864
inhibits Rac activation by binding to Rac to compete with the
GEF binding or to destabilize the bound nucleotide, respectivelyª2012 Elsevier Ltd All rights reserved 493
Figure 7. CPYPP Blocks Activation of T
Cells and pDCs
(A) Inhibition by CPYPP of Rac activation in T cells
stimulated with anti-CD3ε antibody. Results are
expressed as the ratio of GTP-bound Rac to total
Rac after normalization of the 0.5-min value of
DMSO-treated cells to an arbitrary unit 1. Data are
mean ± SD of three independent experiments.
(B) Inhibition by CPYPP of MLR between C57BL/6
and B10.BRmice. Data are mean ± SD of triplicate
samples and are representative of three indepen-
dent experiments.
(C) Inhibition by CPYPP of Rac activation in pDCs
stimulated with CpG-A. Results are expressed as
the ratio of GTP-bound Rac to total Rac after
normalization of the 1-min value of DMSO-treated
cells to an arbitrary unit 1. Data are mean ± SD of
three independent experiments.
(D) InhibitionbyCPYPPofTLR9–mediated type I IFN
induction in pDCs. Data are mean ± SD of triplicate
samples and are representative of three indepen-
dent experiments. (A–D) *p < 0.05; **p < 0.01.
See also Figure S6.
Chemistry & Biology
An Inhibitor that Blocks Rac Activation by DOCK2(Gao et al., 2004; Shutes et al., 2007). On the other hand, IPA-3 is
an inhibitor targeting p21-activated kinase (PAK), a downstream
effector of Rac (Deacon et al., 2008). However, because Rac and
PAK isoforms are expressed in many cell-types, they are not
ideal targets to control immune responses. Unlike these mole-
cules, DOCK2 expression is limited to hematopoietic cells (Fukui
et al., 2001). More importantly, DOCK2 is a Rac activator
essential for migration and activation of lymphocytes (Fukui
et al., 2001; Nombela-Arrieta et al., 2004, 2007; Sanui et al.,
2003; Shulman et al., 2006), and its deficiency has been demon-
strated to suppress allograft rejection and autoimmune disease
development (Jiang et al., 2005). Therefore, DOCK2 may serve
as a better therapeutic target for controlling immune-related
disorders.
Here, we have identified CPYPP as a small-molecule inhibitor
of DOCK2. CPYPP bound to DOCK2DHR-2 and inhibited its Rac
GEF activity with IC50 of 22.8 mM. Unfortunately, CPYPP was
not specific to DOCK2 and showed cross-reactivity to other
DOCK-A members, DOCK5 and DOCK180. However, CPYPP
inhibited DOCK2-mediated Rac activation, without affecting
Rac activation by Tiam1 and Trio. Thus, CPYPP is a selective
inhibitor that can distinguish DOCK2 from the classical GEFs.
Although CPYPP is a potentially reactive Michael acceptor,
the SPR-based analysis indicated that CPYPP binds to
DOCK2DHR-2 in a reversible manner. Indeed, when CPYPP was
treated with 2-mercaptoethanol (1 equivalent) in the assay
buffers in the presence of BSA for 1 hr, CPYPP was recovered
quantitatively in intact form without Michael reaction (our un-
published observation). In addition, we confirmed that the
DOCK2DHR-2 treated with CPYPP is functionally reversible.
Therefore, inhibitory activity of CPYPP is not due to covalent
modification of DOCK2.
CPYPP and its analogs can be readily synthesized in practical
scales. The synthetic route includes convergent Knoevenagel
condensation between aldehydes and pyrazolidinediones,
allowing for rapid supply of structurally diverse analogs of
CPYPP. Current structure–activity relationship studies clarified494 Chemistry & Biology 19, 488–497, April 20, 2012 ª2012 Elsevierthe critical importance of the electron-deficient double bonds
in the compounds, conjugated to the two carbonyl groups of
the pyrozolidinedione part, for their binding and inhibitory activ-
ities. This result suggests the existence of critical hydrophobic
interactions between the inhibitor’s electron-deficient p-orbitals
and the binding pocket of DOCK2DHR-2. Additionally, the molec-
ular flatness of compounds 1, 3, and 4, comparedwith 2 contain-
ing sp3 carbons, would also contribute to their binding ability. On
the other hand, effects of the substituents on the aromatic ring
at the conjugated diene moiety on the inhibitory activity are
more difficult to rationalize. An ortho-substituent with an appro-
priate size and electron-withdrawing ability (such as o-chloride
containing 1) seems to be beneficial for the inhibitory activity. If
a chloride substituent exists, however, its position on the
aromatic ring is not very critical (1, 10, and 11). This result may
also support the importance of the electronic characteristics of
inhibitors’ p-orbitals for their interaction with DOCK2DHR-2.
We also elucidated the cis-geometry of C4=C10 double bond
in CPYPP as an additional structural requirement for the inhibi-
tory activity. Because the double bond geometry was labile
and readily equilibrated each other in a solution state, pure
isomers were hardly separable. However, we fortunately found
that the active cis-isomer 12 could be conveniently isolated in
a gram scale through crystallization. The olefin geometry is
stable in a solid state. In addition, trans-isomer 13 was isolated
in a sub-mg scale by silica gel column chromatography.
Comparison of the inhibitory activity between 12 and 13 demon-
strated that the inhibitory activity resides in the cis-isomer 12.
Therefore, DOCK2DHR-2 differentiates bent (cis) or linear (trans)
global structure of CPYPP.
Although calcineurin inhibitors such as cyclosporine and
FK506 have been successfully used to prevent ‘‘unwanted’’
immune responses, development of novel immunosuppressants
with different actions is required to reduce their side effects. In
this respect, DOCK2 also would be a good drug target, because
DOCK2 deficiency has been demonstrated to synergistically
act with FK506 in controlling transplant rejection (Jiang et al.,Ltd All rights reserved
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for Rac activation in lymphocytes, treatment with CPYPP almost
completely abolished chemokine receptor- and TCR-mediated
Rac activation in lymphocytes, resulting in marked reduction
of chemotactic response and T cell activation. In addition,
we found that TLR9-mediated IFN-a induction is selectively
inhibited in pDCs treated with CPYPP. These results indicate
that CPYPP is able to block effectively DOCK2-mediated
inflammatory responses. Therefore, pharmacological inhibition
of DOCK2 could be an attractive therapeutic strategy for con-
trolling immune-related disorders, such as autoimmune
diseases and transplant rejection, caused by tissue infiltration
of activated lymphocytes. Design and synthesis of geometrically
constrained molecules with the electronic and structural pro-
perties identified in this study will lead to development of more
potent and more selective DOCK2 inhibitors that can be used
as a drug lead.
SIGNIFICANCE
DOCK2, a mammalian homolog of Caenorhabditis elegans
CED-5 and Drosophila melanogaster Myoblast city, is an
atypical Rac activator predominantly expressed in hemato-
poietic cells. Although DOCK2 does not contain Dbl
homology domain typically found in guanine nucleotide
exchange factors (GEFs), DOCK2 mediates the GTP-GDP
exchange reaction for Rac through its DHR-2 domain.
DOCK2 plays a key role in migration and activation of
lymphocytes, and its deficiency suppresses allograft
rejection and autoimmune disease development in mice.
Therefore, DOCK2 may serve as a molecular target for
controlling immune-related disorders. Here, we have identi-
fied 4-[30-(200-chlorophenyl)-20-propen-10-ylidene]-1-phenyl-
3,5-pyrazolidinedione (CPYPP) as a small-molecule inhibitor
of DOCK2. CPYPP bound to DOCK2 DHR-2 domain in a
reversible manner and inhibited its catalytic activity, without
affecting Rac activation by the classical GEFs. The struc-
ture–activity relationship study revealed the importance of
the electron-deficient double bonds, a chloride substituent
on the aromatic ring, and the cis-geometry for inhibitory
activity of CPYPP. When lymphocytes were treated with
CPYPP, both chemokine receptor- and antigen receptor-
mediated Rac activation were blocked, resulting in marked
reduction of chemotactic response and T cell activation.
These results suggest that pharmacological inhibition of
DOCK2 could be a therapeutic strategy for controlling
immune-related disorders, and provide a rational of and
a chemical scaffold for development of the DOCK2-target-
ing immunosuppressant.
EXPERIMENTAL PROCEDURES
Chemical Compounds
A total of 9,392 chemical compounds used for the initial screening were ob-
tained from Open Innovation Center for Drug Discovery at The University of
Tokyo, Japan. The synthesis and purification of CPYPP and its analogs are
described in Supplemental Experimental Procedures in detail. Compounds
were dissolved in DMSO, and diluted with appropriate buffers immediately
before use. The percentage of DMSO used for cellular assays or in vitro GEF
assay was 0.2% or 1%, respectively.Chemistry & Biology 19,Plasmids
For expression of DOCK2, Tiam1, or Trio DH-D1/PH-D1 domain in mammalian
cells, their cDNAswere amplified by PCRwith primers encoding hemagglutinin
(HA) tag, and cloned into pCI (Promega) or pcDNA-His/max (Invitrogen). The
pET-SUMO vector was created by subcloning SUMO cDNA into pET-28a
vector (Novagen). The genes encoding DOCK2DHR-2, DOCK2DHR-2DlobeA,
DOCK180DHR-2DlobeA, DOCK5DHR-2DlobeA, and DOCK9DHR-2DlobeA were cloned
into the pET-SUMO to express fusion proteins with His tag at their N terminus,
which were used for in vitro GEF assays, STD-NMR assays, and SPR-based
binding assays. For screening of chemical compounds, DOCK2DHR-2 with
trigger factor (TF) at the N terminus and streptavidin binding protein (SBP) at
the C terminus was created using pET-22b vector. The gene encoding Rac1
or Cdc42 was cloned into pGEX-6P-1 (GE Healthcare) to express gluta-
thione-S-transferase (GST)-fusion protein.
Screening of Chemical Library
An ELISA was employed to screen for chemical compounds that can inhibit
interaction between DOCK2DHR-2 and Rac. Briefly, 96-well polystyrene plates
were coated overnight with streptavidin (250 ng per well) dissolved in 50 mM
carbonate buffer (pH 9.6). Each well was blocked with 150 ml of 5% skim
milk in TBST (20 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20, pH7.5) at
room temperature for 1 hr. After the wells were rinsed with TBST, recombinant
TF-DOCK2DHR-2-SBP (50 ml, 60 mg/ml in TBST) was added to each well and
incubated at room temperature for 1 hr. The wells were then rinsed with
TBST supplemented with 1 mM EDTA. To each well, the library component
or vehicle (50 ml, 200 mM in TBST/1mMEDTA/2%DMSO)was added and incu-
bated at room temperature for 1 hr. After incubation, GST-Rac1 or GST-Cdc42
(50 ml, 50 mg/ml in TBST/1 mM EDTA) was added to each well and incubated
for 1 hr at room temperature. The wells were then rinsed with 150 ml of TBST/
1 mM EDTA. Horseradish peroxidase-conjugated anti-GST antibody (50 ml, in
TBST/1 mM EDTA) wad added to each well and incubated for 1 hr at room
temperature. After the wells were rinsed with TBST/1 mM EDTA, peroxidase
substrate (50 ml, 0.4 mg/ml o-phenylenediamine and 0.01% H2O2 in 0.1 M
citrate buffer, pH 5.0) was added to each well and incubated for 30–60 min
at room temperature. The absorbance was measured at 450 nm with a Multis-
kan Bichromatic plate reader (Labsystems) and compensated by subtracting
‘‘blank’’ absorbance of the well into which GST-Cdc42 was added. Percent
inhibition was calculated as follows: [(optical density with vehicle alone) –
(optical density with sample)]/(optical density with vehicle alone) 3 100.
Compounds were regarded as potential hits if they had an inhibitory effect
>40%.
Mice
DOCK2–/– and DOCK2-GFP knock-in mice have been described previously
(Fukui et al., 2001; Nishikimi et al., 2009). All mice were maintained under
specific pathogen-free conditions in the animal facility of Kyushu University.
Animal protocols were approved by the committee of Ethics on Animal
Experiment, Faculty of Medical Sciences, Kyushu University.
In Vitro GEF Assays
Recombinant GEF protein diluted in exchange buffer (20 mM MES-NaOH,
150 mM NaCl, 10 mM MgCl2, 0.2 mg/ml BSA, 20 mM GDP, pH 7.0) was
incubated with chemical compounds or DMSO (vehicle) for 2–30 min in the
dark at room temperature. UnboundCPYPPwas removed using a spin column
gel filtration (Edge Bio) at this stage when the functional reversibility of
DOCK2DHR-2 was analyzed. Recombinant Rac or Cdc42 (15 mM) was loaded
with GDP in the same reaction buffer on ice for 30min. GDP-loadedG-proteins
(100 ml) were allowed to equilibrate in exchange buffer supplemented with N-
methylanthraniloyl (mant)-GTP (3.6 mM; Jena Bioscience) or BODIPY-FL-GTP
(3.6 mM; Invitrogen) for 8 min. After equilibration, pretreated GEF (50 ml) was
added to the mixtures and the change of mant-GTP fluorescence (excitation =
360 nm, emission = 440 nm) or BODIPY-FL fluorescence (excitation = 488 nm,
emission = 514 nm) was monitored at 30C using a XS-N spectrofluorimeter
(Molecular Devices). For IC50 determination, the initial slope for each reaction
was determined using a curve fitting function of the GraphPad Prism 5
program (GraphPad Software), and plotted as a function of compound
concentrations. The slope in the absence of compound was set as ‘‘100%
activity.’’488–497, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 495
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All NMR spectra were recorded at 298 K on a Bruker Avance 600-MHz
spectrometer equipped with a TXI cryoprobe. NMR samples were prepared
in 0.4 ml of 99.9% 2H2O buffer containing 10 mM Tris-d8-
2HCl, pH 8.0, and
10 mM MgCl2. Protein concentrations were 1 mM. CPYPP was dissolved in
99.96% DMSO-d6 at 2 mg/ml, and added to the protein samples at a final
concentration of 100 mM. STD NMR spectra were acquired with the pulse
sequence as described (Mayer and Meyer, 2001). The on-resonance irradia-
tion of the protein methyl signal region was set at a chemical shift of 0.2
ppm, and the off-resonance irradiation was set at 30 ppm, where no protein
signals were present, with a total saturation time of 2 s. The suppression of
the residual 1H2HO signal was achieved by the WATERGATE technique. The
STD effect was verified by efficient cancellation of the impurity peaks.
SPR-Based Binding Assays
SPR-based binding assays were performed using a Biacore T200 (GE Health-
care). His-SUMO-DOCK2DHR-2DlobeA was immobilized on NTA Sensor Chip
(GE Healthcare) with a covalent coupling of His-tagged protein to nitrilotriace-
tic acid (NTA) biosensor surface (Willard and Siderovski, 2006). NTA Sensor
Chip was washed with 0.35 M EDTA for 60 s (10 ml/min) followed by extra
wash with a buffer (10 mM HEPES, pH 7.4; 150 mM NaCl, 50 mM EDTA,
0.1% Tween 20). Then the chip was activated with 500 mM NiCl2 for 60 s
(10 ml/min) followed by extra wash with 3 mM EDTA. Finally, His-SUMO-
DOCK2DHR-2DlobeA was immobilized on the chip by amine coupling (Amine
Coupling Kit, GE Healthcare) after injection of EDC (1-ethyl-3(3-dimethylami-
nopropyl)-carbodiimide hydrochloride)/NHS (10 ml/min, 7 min) and His-
SUMO-DOCK2DHR-2 (10 ml/min, 7 min), and deactivation with ethanol amine
(10 ml/min, 7 min). We could capture significant amount of His-SUMO-
DOCK2DHR-2DlobeA (3,000 RU) for affinity experiments. SPR measurements
were carried out with a running buffer (10 mM HEPES, pH 7.4; 150 mM
NaCl, 50 mM EDTA, 0.1% Tween 20, and 8% DMSO). For this purpose,
compounds were diluted with the running buffer to keep DMSO concentration
at 8%. Then the sample was injected for 60 s (contact phase), and 180 s
of buffer flow (dissociation phase) was followed. The flow rate was set at
30 ml/min. For extra wash, 50% DMSO was used. The binding response
(RU) of compounds to His-SUMO-DOCK2DHR-2DlobeA was determined with
the Biacore T200 evaluation software.
Cell Preparation
pDCs were prepared from bone marrow (BM) cells using Flt3 ligand as
described previously (Gotoh et al., 2010). T cells and B cells were isolated
from spleen and lymph nodes using Pan-T cell isolation kit and B cell isolation
kit (both from Myltenii Biotec), respectively. CD4+ T cells were isolated by
magnetic sorting with Dynabead Mouse CD4 followed by treatment with
DETACHaBEAD Mouse CD4 (both from Dynal). Cell viability was determined
with CytoTox 96 nonradioactive cytotoxicity assay (Promega) according to
the manufacture’s instructions.
Rac Activation Assays
Before assays, cells were stimulated with CCL21 (1 mg/ml), CXCL13 (1 mg/ml),
anti-CD3ε antibody (145-2c11; 10 mg/ml) followed by crosslinking with anti-
hamster IgG (10 mg/ml), or CpG-A (3 mM). Aliquots of the cell extracts were
kept for total lysate controls, and the remaining extracts were incubated
with GST-fusion Rac-binding domain of PAK1 at 4C for 60 min. The bound
proteins and the same amounts of total lysates were analyzed by SDS-
PAGE, and blots were probed with anti-Rac antibody (23A8, Millipore).
Chemotaxis Assays
Transwell chemotaxis assays were performed using CCL21 (300 ng/ml) or
CXCL13 (2 mg/ml) as a chemoattractant for T cells or B cells, respectively. After
incubation for 2 hr at 37C, spleen cells migrated to the lower chamber were
collected, and stained for Thy1.2 and B220. The percentage of migrated cells
was calculated by dividing the number of Thy1.2+ cells (T cells) or B220+ cells
(B cells) in the lower chamber by the number of input cells.
MLR
T cells (3 3 105) from C57BL/6 mice were cultured with irradiated spleen
cells (1 3 106) from B10.BR or C57BL/6 mice in the presence of various496 Chemistry & Biology 19, 488–497, April 20, 2012 ª2012 Elsevierconcentrations of CPYPP or DMSO for 84 hr, and [3H]-thymidine (0.037
MBq) was added during the final 16 hr of the culture. Cells were harvested
on glass filter paper, and the incorporated radioactivity was measured with
a liquid scintillation counter.
Measurement of Cytokine Production
Flt3 ligand-induced BM-derived pDCs were stimulated with CpG-A (3 mM)
for 24 hr in the presence of CPYPP or DMSO. Concentrations of IFN-a (R&D
Systems) and IL-12p40 (Thermo Fisher Scientific) in cell-culture supernatants
were measured by ELISA kit.
In Vivo Homing Assays
Spleen cells (1 3 108) isolated from DOCK2-GFP knock-in mice were trans-
ferred intravenously into C57BL/6 mice that had been treated intraperitoneally
with 100 ml of CPYPP (50mg/ml in DMSO) or intravenously with 50 ml of CPYPP
(1 mg/ml in DMSO) 1 hr before the transfer. Mice were sacrificed 1 hr later, and
cells were prepared from the spleen and the peripheral lymph nodes. Cells
were then stained for CD3ε, and the percentages of migrated T cells were
calculated.
Measurement of Plasma Concentration of CPYPP
The plasma concentration of CPYPP was determined using LC-MS/MS
(Prominence 2000 series liquid chromatography system, Shimadzu, coupled
to an API-3000 mass spectrometer, Applied Biosystems). A CPYPP standard
curve using 5 ml of serially diluted CPYPP in DMSO into 50 ml of plasma (final
concentration range from 0.01 to 30 mg/ml) was used to determine CPYPP
concentration in plasma. Following protein precipitation by acetonitrile con-
taining 0.1 mg/ml of diazepam (internal standard), samples were cleared by
centrifugation (15 min, 3,500 rpm, 4C) and fractionated on a Capcell PAK
C18 MG column (3 mm, 2.0 3 35 mm; Shiseido) at 50C using a 0.1% formic
acid/water to 0.1% formic acid/acetonitrile gradient with a flow rate of
0.3 ml/min. Detection of CPYPP and diazepam was carried out by positive
electrospray ionization mode with transitions of m/z 325–164 and m/z
285–193, respectively. The ratio of chromatographic peak areas of CPYPP
to diazepam was used to calculate the plasma CPYPP concentration and
expressed as mM by unit conversion.
Measurement of Intracellular CPYPP Content
An oil filtration assay was applied to determine relative intracellular accumula-
tion of CPYPP by using Transporter Suspension Assay Kit (BD Biosciences).
Microcentrifuge tubes from the kit were conditioned by addition of 100 ml of
2 N NaOH solution followed by layering filtration oil onto the NaOH solution.
Spleen cells of BALB/c mice (1 3 107/ml) were incubated in RPMI1640
medium supplemented with 0.5% BSA or 10% FCS in the presence or
absence of 100 mM CPYPP. After 1 or 5 hr of incubation at 37C, the spleno-
cyte suspension in each culture media was loaded onto the oil layer and
centrifuged (12,000 rpm, 30 s) to pellet cells in the NaOH layer, enabling quick
wash and splenocyte collection. Splenocyte suspension in NaOH were taken
off by scissoring microcentrifuge tube and aspirating the remaining oil, then
incubated at 37C for 10min for solubilization. These samples were neutralized
by HCl and diluted by acetonitrile with 0.1 mg/ml of diazepam. Samples were
injected into the LC-MS/MS system to detect peak areas of CPYPP and diaz-
epam. The ratio of peak areas of CPYPP to diazepam was used to compare
intracellular content of CPYPP.
Statistical Analysis
Statistical analyses were performed using one-way analysis of variance
(ANOVA) followed by Dunnett’s test (Figures 2D, 5B, 6C, 6D, 7B, and 7D) or
two-tailed Student’s t test (Figures 3D, 6A, 6B, 6E, 7A, and 7C). Analyses
were done with GraphPad Prism 5 software.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
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